Status:
COMPLETED
Epidermal Growth Factor Receptor and K-ras Mutations in Patients With Stage III Non-Small Cell Lung Cancer
Lead Sponsor:
Alliance for Clinical Trials in Oncology
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
RATIONALE: Collecting and storing samples of tissue from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related...
Detailed Description
OBJECTIVES: * Determine the frequency of epidermal growth factor receptor (EGFR) and K-ras mutations in patients with stage III non-small cell lung cancer (NSCLC) treated on CALGB 30106. * Correlate ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Eligible patients had histologic documentation of un- treated stage III NSCLC.
- Radiation oncologist confirmation was required that radiation could be given per protocol.
- Eastern Cooperative Group Criteria Performance Status of 0 to 2
- Tumor specimen paraffin block or unstained slides and standard initial laboratory tests
- Signed institutional review board-approved, protocol-specific in- formed consent in accordance with federal and institutional guidelines
- Exclusion criteria:
- 1\. Patients with scalene, supraclavicular, or contralateral hilar lymph node involvement, or direct invasion of the vertebral body or with a pleural effusion were ineligible.
Exclusion
Key Trial Info
Start Date :
November 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00898924
Start Date
November 1 2005
End Date
July 1 2010
Last Update
June 29 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.